Santhera Pharmaceuticals, today announces an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the reimbursement for AGAMREE (vamorolone) for the treatment of Duchenne Muscular Dystrophy (DMD). This milestone makes AGAMREE the first product to receive an agreed federal price in Germany for the treatment of DMD in patients 4 years of age and older, independent of the underlying genetic mutation.
First Treatment in Germany
AGAMREE is the first product to receive an agreed federal price in Germany for the treatment of all DMD patients 4 years and older, and independent of genetic mutation. [Read More: What is AGAMREE (vamorolone)?]
Cost of AGAMREE (vamorolone)
The agreement secured with the GKV-SV reflects Santhera’s commitment to ensuring broad patient access while supporting sustainable healthcare outcomes. The agreed ex-factory price is EUR 3,612.50 per 100ml bottle, translating into approximately EUR 52,000 per year for an average patient when considering required rebates, patient weight and dosing.
Read More: Clinical Trials for Duchenne (List of All Researches)
